The Cytogenefics Core has been approved as an established Shared Resource of DF/HCC since it's founding. Charies Lee has directed the facility since 2006, after serving as its Assistant Director for six years. Cytogenetic studies can provide insight into regions of the genome that are pathogenetic in various neoplasms leading to an understanding ofthe molecular pathways participating in the biology of cancer. An invaluable function of the Cytogenetics Core is access to consultation for experimental design and data interpretation with the Core Directors. Consultation provides the investigator with guidance and advice regarding the best approach for the goal(s) of a specific study. Services of the Core are primarily focused on human and mouse cytogenetics and include: 1) conventional karyotyping of fissue specimens and cell lines, 2) fluorescence in situ hybridization (FISH) for metaphase and interphase preparations, and 3) comparative genomic hybridization (CGH) on microarrays. Director: Charies Lee, PhD(MWH) Category: 1.15 (Cytogenetics) Management: Joint (Cancer Center and Institutional).

Public Health Relevance

The mission of the Cytogenetics Core is to provide state-of-the-art cytogenetics services to DF/HCC scientists to facilitate investigations of the pathogenesis and pathobiology of neoplasia. Cytogenetic studies may also be important in establishing a diagnosis for correlation with clinical outcome. Cytogenetics is a fundamental adjunct to a variety of investigations underway, including basic and translational research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006516-49
Application #
8601482
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
49
Fiscal Year
2014
Total Cost
$182,287
Indirect Cost
$60,777
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Oxnard, Geoffrey R; Hu, Yuebi; Mileham, Kathryn F et al. (2018) Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. JAMA Oncol 4:1527-1534
Patil, Prasad; Parmigiani, Giovanni (2018) Training replicable predictors in multiple studies. Proc Natl Acad Sci U S A 115:2578-2583
Agoston, Agoston T; Pham, Thai H; Odze, Robert D et al. (2018) Columnar-Lined Esophagus Develops via Wound Repair in a Surgical Model of Reflux Esophagitis. Cell Mol Gastroenterol Hepatol 6:389-404
Barber, Lauren; Gerke, Travis; Markt, Sarah C et al. (2018) Family History of Breast or Prostate Cancer and Prostate Cancer Risk. Clin Cancer Res 24:5910-5917
Kwee, Brian J; Budina, Erica; Najibi, Alexander J et al. (2018) CD4 T-cells regulate angiogenesis and myogenesis. Biomaterials 178:109-121
Madsen, Thomas; Braun, Danielle; Peng, Gang et al. (2018) Efficient computation of the joint probability of multiple inherited risk alleles from pedigree data. Genet Epidemiol 42:528-538
Chen, Jingjing; Guccini, Ilaria; Di Mitri, Diletta et al. (2018) Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer. Nat Genet 50:219-228
Li, Andrew G; Murphy, Elizabeth C; Culhane, Aedin C et al. (2018) BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1? activation. Proc Natl Acad Sci U S A 115:E9600-E9609
McBrayer, Samuel K; Mayers, Jared R; DiNatale, Gabriel J et al. (2018) Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. Cell 175:101-116.e25
Stopsack, Konrad H; Gonzalez-Feliciano, Amparo G; Peisch, Samuel F et al. (2018) A Prospective Study of Aspirin Use and Prostate Cancer Risk by TMPRSS2:ERG Status. Cancer Epidemiol Biomarkers Prev 27:1231-1233

Showing the most recent 10 out of 411 publications